Mackenzie Financial Corp purchased a new stake in shares of Enfusion, Inc. (NYSE:ENFN – Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The fund purchased 22,517 shares of the company’s stock, valued at approximately $192,000.
Other institutional investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new stake in Enfusion in the first quarter valued at approximately $44,000. RiverPark Advisors LLC purchased a new stake in shares of Enfusion during the 2nd quarter valued at $68,000. Arizona State Retirement System bought a new stake in shares of Enfusion during the 2nd quarter worth $86,000. Price T Rowe Associates Inc. MD purchased a new position in Enfusion in the first quarter worth $102,000. Finally, Quadrature Capital Ltd bought a new position in Enfusion in the first quarter valued at $109,000. Institutional investors own 81.05% of the company’s stock.
Enfusion Trading Down 0.6 %
Shares of NYSE ENFN opened at $8.95 on Tuesday. The stock’s 50-day moving average is $8.52 and its 200 day moving average is $8.89. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 298.17, a P/E/G ratio of 2.63 and a beta of 0.92. Enfusion, Inc. has a 1-year low of $7.52 and a 1-year high of $10.45.
Enfusion Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Further Reading
- Five stocks we like better than Enfusion
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Energy and Oil Stocks Explained
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- How to Calculate Stock Profit
- RPM International Thrives in Rate-Cut Driven Construction Rally
Want to see what other hedge funds are holding ENFN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enfusion, Inc. (NYSE:ENFN – Free Report).
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.